Verve Therapeutics is a leading genetic medicines company based in the United States. Specializing in cardiovascular disease care, the company is revolutionizing treatment through single-course gene editing medicines. With a focus on genes like PCSK9 and ANGPTL3, Verve Therapeutics is dedicated to lowering blood lipids and addressing the root cause of cardiovascular disease. With an ESG score of 23.6, the company is considered a medium risk investment.